152 related articles for article (PubMed ID: 30219371)
21. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects.
Botwright S; Holroyd T; Nanda S; Bloem P; Griffiths UK; Sidibe A; Hutubessy RCW
PLoS One; 2017; 12(10):e0182663. PubMed ID: 29016596
[TBL] [Abstract][Full Text] [Related]
22. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts.
Jit M; Levin C; Brisson M; Levin A; Resch S; Berkhof J; Kim J; Hutubessy R
BMC Med; 2013 Jan; 11():23. PubMed ID: 23363734
[TBL] [Abstract][Full Text] [Related]
23. Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.
Lim ASE; Lim RBT
Vaccine; 2019 Sep; 37(41):6030-6038. PubMed ID: 31473002
[TBL] [Abstract][Full Text] [Related]
24. Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: Global and national stakeholder perspectives.
Guillaume D; Waheed DE; Schlieff M; Muralidharan K; Vorsters A; Limaye R
Hum Vaccin Immunother; 2022 Dec; 18(7):2150454. PubMed ID: 36485172
[TBL] [Abstract][Full Text] [Related]
25. [Vaccines against human papillomavirus (HPV); between registration and implementation].
van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
[TBL] [Abstract][Full Text] [Related]
26. Mind the gaps: what's missing from current economic evaluations of universal HPV vaccination?
Marsh K; Chapman R; Baggaley RF; Largeron N; Bresse X
Vaccine; 2014 Jun; 32(30):3732-9. PubMed ID: 24837538
[TBL] [Abstract][Full Text] [Related]
27. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
28. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
29. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
30. Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries.
Kostaras D; Karampli E; Athanasakis K
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):147-158. PubMed ID: 30501434
[TBL] [Abstract][Full Text] [Related]
31. Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.
Vanagas G; Padaiga Z
Scand J Public Health; 2012 Jul; 40(5):406-11. PubMed ID: 22821227
[TBL] [Abstract][Full Text] [Related]
32. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.
Aljunid S; Maimaiti N; Nur AM; Noor MRM; Wan Puteh SE
BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814
[TBL] [Abstract][Full Text] [Related]
34. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
Jit M; Demarteau N; Elbasha E; Ginsberg G; Kim J; Praditsitthikorn N; Sinanovic E; Hutubessy R
BMC Med; 2011 May; 9():54. PubMed ID: 21569406
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.
Marra F; Cloutier K; Oteng B; Marra C; Ogilvie G
Pharmacoeconomics; 2009; 27(2):127-47. PubMed ID: 19254046
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
37. HPV vaccination in France: uptake, costs and issues for the National Health Insurance.
Fagot JP; Boutrelle A; Ricordeau P; Weill A; Allemand H
Vaccine; 2011 Apr; 29(19):3610-6. PubMed ID: 21382486
[TBL] [Abstract][Full Text] [Related]
38. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
[TBL] [Abstract][Full Text] [Related]
39. Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique.
Haidari LA; Brown ST; Constenla D; Zenkov E; Ferguson M; de Broucker G; Ozawa S; Clark S; Portnoy A; Lee BY
Sex Transm Dis; 2017 Apr; 44(4):222-226. PubMed ID: 28282648
[TBL] [Abstract][Full Text] [Related]
40. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
